Bortezomib and etoposide combinations exert synergistic effects on the human prostate cancer cell line PC-3

Aras,Bekir; Yerlikaya,Azmi

doi:10.3892/ol.2016.4340

Bortezomib and etoposide combinations exert synergistic effects on the human prostate cancer cell line PC-3

Authors:
- Bekir Aras
- Azmi Yerlikaya
View Affiliations

Affiliations: Department of Urology, Faculty of Medicine, Dumlupınar University, Kütahya 43100, Turkey, Department of Medical Biology, Faculty of Medicine, Dumlupınar University, Kütahya 43100, Turkey
Published online on: March 16, 2016 https://doi.org/10.3892/ol.2016.4340
Pages: 3179-3184

Metrics: Total Views: 0 (Spandidos Publications: | PMC Statistics: )

Metrics: Total PDF Downloads: 0 (Spandidos Publications: | PMC Statistics: )

Cited By (CrossRef): 0 citations Loading Articles...

Abstract

Novel treatment modalities are urgently required for androgen-independent prostate cancer. In order to develop an alternative treatment for prostate cancer, the cytotoxic effects of the 26S proteasome inhibitor bortezomib, either alone or in combination with the two commonly used chemotherapeutic agents irinotecan and etoposide, on the human prostate cancer cell line PC‑3 were evaluated in the present study. The PC‑3 cell line was maintained in Dulbecco's modified Eagle's medium with 10% fetal bovine serum and treated with various doses of bortezomib, irinotecan, etoposide or their combinations. The growth inhibitory and cytotoxic effects were determined by water‑soluble tetrazolium (WST)‑1 assay, 3‑(4,5‑dimethylthiazol‑2‑yl)‑2,5‑diphenyltetrazolium bromide (MTT) assay or iCELLigence system. The combination index values were determined by the Chou‑Talalay method. The half maximal inhibitory concentration (IC50) value of bortezomib on the PC‑3 cell line was determined to be 53.4 nM by WST‑1 assay, whereas the IC50 values of irinotecan and etoposide were determined to be 2.1 and 26.5 µM, respectively. These results suggest that the 26S proteasome inhibitor bortezomib is more potent, compared with irinotecan and etoposide, in the androgen‑insensitive and tumor protein p53‑null cell line PC‑3. The combined effects of bortezomib+irinotecan and bortezomib+etoposide were also tested on PC‑3 cells. The effect of bortezomib+irinotecan combination was not significantly different than that produced by either monotherapy, according to the results of iCELLigence system and MTT assay. However, 40 nM bortezomib+5 µM etoposide or 40 nM bortezomib+20 µM etoposide combinations were observed to be more effective than each drug tested alone. The results of the current study suggest that bortezomib and etoposide combination may be additionally evaluated in clinical trials for the treatment of hormone-refractory prostate cancer.

View Figures

View References

1	Russell PJ and Kingsley EA: Human prostate cancer cell lines. Methods Mol Med. 81:21–39. 2003.PubMed/NCBI
2	Whang PG, Gamradt SC, Gates JJ and Lieberman JR: Effects of the proteasome inhibitor bortezomib on osteolytic human prostate cancer cell metastases. Prostate Cancer Prostatic Dis. 8:327–334. 2005. View Article : Google Scholar : PubMed/NCBI
3	Potosky AL, Miller BA, Albertsen PC and Kramer BS: The role of increasing detection in the rising incidence of prostate cancer. JAMA. 273:548–552. 1995. View Article : Google Scholar : PubMed/NCBI
4	Hanks GE, Krall JM, Hanlon AL, Asbell SO, Pilepich MV and Owen JB: Patterns of Care and RTOG studies in prostate cancer: Long-term survival, hazard rate observations, and possibilities of cure. Int J Radiat Oncol Biol Phys. 28:39–45. 1994. View Article : Google Scholar : PubMed/NCBI
5	Zincke H, Oesterling JE, Blute ML, Bergstralh EJ, Myers RP and Barrett DM: Long-term (15 years) results after radical prostatectomy for clinically localized (stage T2c or lower) prostate cancer. J Urol. 152:1850–1857. 1994.PubMed/NCBI
6	Crawford ED, Eisenberger MA, McLeod DG, Spaulding JT, Benson R, Dorr FA, Blumenstein BA, Davis MA and Goodman PJ: A controlled trial of leuprolide with and without flutamide in prostatic carcinoma. N Engl J Med. 321:419–424. 1989. View Article : Google Scholar : PubMed/NCBI
7	Eisenberger MA, Crawford ED, Wolf M, Blumenstein B, McLeod DG, Benson R, Dorr FA, Benson M and Spaulding JT: Prognostic factors in stage D2 prostate cancer; important implications for future trials: Results of a cooperative intergroup study (INT.0036). The National Cancer Institute Intergroup Study #0036. Semin Oncol. 21:613–619. 1994.PubMed/NCBI
8	Newling DW, Denis L and Vermeylen K: Orchiectomy versus goserelin and flutamide in the treatment of newly diagnosed metastatic prostate cancer. Analysis of the criteria of evaluation used in the European Organization for Research and Treatment of Cancer - Genitourinary Group Study 30853. Cancer. 72(Suppl 12): 3793–3798. 1993. View Article : Google Scholar : PubMed/NCBI
9	Bracarda S, Logothetis C, Sternberg CN and Oudard S: Current and emerging treatment modalities for metastatic castration- resistant prostate cancer. BJU Int. 107(Suppl 2): 13–20. 2011. View Article : Google Scholar : PubMed/NCBI
10	Sartor O, Halstead M and Katz L: Improving outcomes with recent advances in chemotherapy for castrate-resistant prostate cancer. Clin Genitourin Cancer. 8:23–28. 2010. View Article : Google Scholar : PubMed/NCBI
11	Papandreou CN and Logothetis CJ: Bortezomib as a potential treatment for prostate cancer. Cancer Res. 64:5036–5043. 2004. View Article : Google Scholar : PubMed/NCBI
12	Yerlikaya A and Yöntem M: The significance of ubiquitin proteasome pathway in cancer development. Recent Patents Anticancer Drug Discov. 8:298–309. 2013. View Article : Google Scholar
13	Yerlikaya A and Erin N: Differential sensitivity of breast cancer and melanoma cells to proteasome inhibitor Velcade. Int J Mol Med. 22:817–823. 2008.PubMed/NCBI
14	Yerlikaya A, Okur E and Ulukaya E: The p53-independent induction of apoptosis in breast cancer cells in response to proteasome inhibitor bortezomib. Tumour Biol. 33:1385–1392. 2012. View Article : Google Scholar : PubMed/NCBI
15	Freshney RI: Cytotoxicity. Culture of Animal Cells: A Manual of Basic Technique (5th). John Wiley and Sons Inc. (Hoboken, NJ). 3592005.
16	Pham LV, Tamayo AT, Li C, Bornmann W, Priebe W and Ford RJ: Degrasyn potentiates the antitumor effects of bortezomib in mantle cell lymphoma cells in vitro and in vivo: Therapeutic implications. Mol Cancer Ther. 9:2026–2036. 2010. View Article : Google Scholar : PubMed/NCBI
17	Adams J, Palombella VJ, Sausville EA, Johnson J, Destree A, Lazarus DD, Maas J, Pien CS, Prakash S and Elliott PJ: Proteasome inhibitors: A novel class of potent and effective antitumor agents. Cancer Res. 59:2615–2622. 1999.PubMed/NCBI
18	Kiliccioglu I, Konac E, Varol N, Gurocak S and Bilen Yucel C: Apoptotic effects of proteasome and histone deacetylase inhibitors in prostate cancer cell lines. Genet Mol Res. 13:3721–3731. 2014. View Article : Google Scholar : PubMed/NCBI
19	Williams S, Pettaway C, Song R, Papandreou C, Logothetis C and McConkey DJ: Differential effects of the proteasome inhibitor bortezomib on apoptosis and angiogenesis in human prostate tumor xenografts. Mol Cancer Ther. 2:835–843. 2003.PubMed/NCBI
20	Sato A and Asano T, Ito K and Asano T: Vorinostat and bortezomib synergistically cause ubiquitinated protein accumulation in prostate cancer cells. J Urol. 188:2410–2418. 2012. View Article : Google Scholar : PubMed/NCBI
21	Ocean AJ, Christos P, Sparano JA, Shah MA, Yantiss RK, Cheng J, Lin J, Papetti M, Matulich D, Schnoll-Sussman F, et al: Phase II trial of bortezomib alone or in combination with irinotecan in patients with adenocarcinoma of the gastroesophageal junction or stomach. Invest New Drugs. 32:542–548. 2014. View Article : Google Scholar : PubMed/NCBI
22	Kozuch PS, Rocha-Lima CM, Dragovich T, Hochster H, O'Neil BH, Atiq OT, Pipas JM, Ryan DP and Lenz HJ: Bortezomib with or without irinotecan in relapsed or refractory colorectal cancer: Results from a randomized phase II study. J Clin Oncol. 26:2320–2326. 2008. View Article : Google Scholar : PubMed/NCBI
23	Horton TM, Perentesis JP, Gamis AS, Alonzo TA, Gerbing RB, Ballard J, Adlard K, Howard DS, Smith FO, Jenkins G, et al: A Phase 2 study of bortezomib combined with either idarubicin/cytarabine or cytarabine/etoposidee in children with relapsed, refractory or secondary acute myeloid leukemia: A report from the Children's Oncology Group. Pediatr Blood Cancer. 61:1754–1760. 2014. View Article : Google Scholar : PubMed/NCBI
24	Petitprez A, Poindessous V, Ouaret D, Regairaz M, Bastian G, Guérin E, Escargueil AE and Larsen A: Acquired irinotecan resistance is accompanied by stable modifications of cell cycle dynamics independent of MSI status. Int J Oncol. 42:1644–1653. 2013.PubMed/NCBI
25	Groh T, Hrabeta J, Khalil MA, Doktorova H, Eckschlager T and Stiborova M: The synergistic effects of DNA-damaging drugs cisplatin and etoposide with a histone deacetylase inhibitor valproate in high-risk neuroblastoma cells. Int J Oncol. 47:343–352. 2015.PubMed/NCBI